Created in 2013 by Prof. Sebastien Gibot, Dr. Marc Derive and Dr. Jean-Jacques Garaud, Inotrem is a French biotech company specializing in the discovery and development of novel treatments in the field of inflammatory pathologies with a focus on critical care.
The Company’s leading product candidate is a TREM-1 inhibitor that aims to control excessive inflammation in severe sepsis patients.
Since its inception Inotrem has received the initial support of the Incubateur Lorrain and the University of Lorraine in Nancy, Région Lorraine, BPI France and Inserm Transfert.
Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano als...